Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Myeloproliferative Neoplasms
- Main trialPhase 1
- “This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.”In the company’s words, NCT07441694 on ClinicalTrials.gov
Other drugs for Myeloproliferative Neoplasms
- Givinostat HydrochlorideItalfarmaco · Phase 3
- NavitoclaxAbbVie · Phase 3
- NavtemadlinKartos Therapeutics, Inc. · Phase 3
- OlverembatinibAscentage Pharma Group Inc. · Phase 3
- Radotinib HClIl-Yang Pharm. Co., Ltd. · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 3
Coming up1
- 24 May 2030Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 24 May 2030 | Study of INCA036978 in Participants With Myeloproliferative Neoplasms |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026